The FDA granted approval for Geneoscopy’s updated stool collection kit for its ColoSense RNA-based colorectal cancer screening test, designed to improve patient compliance. Roche Diagnostics reported a 3% revenue decline in H1 2025, pressured by pricing reforms in China but showed flat sales ex-China. FDA expanded its fast-track priority voucher program to incentivize domestic drug development and affordability measures. GSK’s multiple myeloma drug Blenrep faces FDA review delays after advisory committee concerns. New blood tests and biomarker assays continue to evolve the precision diagnostics landscape, while supply chain resilience remains a prominent industry focus amid accelerated ATMP growth.